ArticleCureus2025
Initial Clinical Outcomes in the Treatment of Brain Metastasis With Gyroscopic Radiosurgery at a Single Institution.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain metastases occur in approximately 20% to 40% of individuals annually diagnosed with cancer. This poor prognostic feature can severely reduce life expectancy and quality of life. Stereotactic radiosurgery (SRS) has been shown to provide excellent tumor control and clinical outcomes. ZAP-X (Zap Surgical Systems Inc., San Carlos, CA, USA) is an innovative self-shielded gyroscopic stereotactic radiosurgery (GRS) system to help further address these needs. In this study, we evaluate the clinical outcomes of patients with brain metastases who have undergone treatment with ZAP-X in a single institution.
methodsMedical records of all patients with brain metastases treated with GRS between May 2021 and May 2023 were reviewed as a retrospective case series. Demographics, clinical symptoms, treatment trajectory, and follow-up data were collected and analyzed.
resultsA total of 46 patients with 140 combined brain metastases were included in this cohort. Of them, 58.7% (N=27) were female patients, and the mean age was 63 years (range 36-82). The primary pathologies were non-small cell lung cancer (NSCLC; N22, 47.8%), breast cancer (N11, 23.9%), melanoma (N5, 10.9%), and others (N8, 17.4%). The prescription dose was 18 Gy if the patient previously received whole-brain radiotherapy (WBRT); otherwise, 20 Gy. All patients received dexamethasone (3x4 mg PO). The most common symptoms included headache (45.7%), motor disturbances (30.4%), and seizures (21.7%). Mean follow-up time was 8.5 months (range 0-19). Systemic response using Response Evaluation Criteria in Solid Tumors (RECIST) criteria was 17.3% complete response, 10.9% partial response, 45.7% stable disease, and 26.1% progression of disease. Tumor control was 73.9% according to the Response Assessment in Neuro-Oncology (RANO) criteria for brain metastases.
conclusionsGRS is a novel image-guided linear accelerator-based, self-shielding gyroscopic radiosurgery platform that does not require a vault. This study shows that GRS achieves comparable results to traditional SRS platforms in the treatment of brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.